Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional…
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal…
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease Genentech, a member of the Roche Group announced today that…
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that…
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 2026 Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap…
Arintra Cuts Coding Costs by Nearly One-Third for Customers, Driving Industry-Leading Retention and 8X Revenue Growth Arintra, the leading GenAI-native autonomous medical coding platform for healthcare organizations, today announced it…
Corazon and Columbia HeartSource Announce Partnership Offering First-of-its-Kind Open-Heart Surgery Accreditation Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a…
RxERP and p‑Chip Corporation Announce Licensing Agreement to Enable Embedded Unit‑Level Digital Identity for DSCSA Compliance and End‑to‑End Pharmaceutical Traceability RxERP, a cloud-hosted, pharmaceutical-first ERP platform, and p‑Chip Corporation (“p‑Chip”),…
Australian Breast Cancer Innovators Close $27M Private Funding Round OncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and…
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals, Inc. today announced the acceptance of three abstracts for presentation at…
iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN/TS 18099 High and Ingenium Level 4 for Injection Attack Detection iProov, the world’s leading provider of science-based biometric…
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties Galderma the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique…